Serum 25-hydroxyvitamin D in amyotrophic lateral sclerosis: mendelian randomization study

Neurobiol Aging. 2020 Mar:87:140.e1-140.e3. doi: 10.1016/j.neurobiolaging.2019.10.024. Epub 2019 Nov 6.

Abstract

We conducted a mendelian randomization study to investigate the association between serum 25-hydroxyvitamin D (S-25OHD) concentrations and amyotrophic lateral sclerosis (ALS). Summary-level data for genetic predictors of S-25OHD concentrations were acquired from 2 genome-wide association studies, comprising up to 79,366 individuals. The corresponding data for ALS were collected from 12,577 ALS cases and 23,475 controls. None of 7 single-nucleotide polymorphisms predicting S-25OHD concentrations was associated with ALS, and there was no overall association of genetic predisposition to higher S-25OHD concentrations with ALS. The odds ratio of ALS per genetically predicted one standard deviation increase of S-25OHD concentrations was 0.96 (95% confidence interval: 0.86-1.08; p = 0.52). We conclude that increasing S-25OHD concentrations will unlikely reduce ALS incidence.

Keywords: Amyotrophic lateral sclerosis; Mendelian randomization; Vitamin D.

MeSH terms

  • Amyotrophic Lateral Sclerosis / genetics*
  • Genetic Predisposition to Disease / genetics
  • Genome-Wide Association Study
  • Humans
  • Mendelian Randomization Analysis
  • Polymorphism, Single Nucleotide
  • Vitamin D / analogs & derivatives*
  • Vitamin D / blood
  • Vitamin D / genetics

Substances

  • Vitamin D
  • 25-hydroxyvitamin D